Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
| PRA Health Sciences, Inc.PRAH · Entity 15912 | Executive VP & CFO | January 16, 2018 | January 18, 2018 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,099 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 68,099 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
PRA Health Sciences, Inc.
Report date January 16, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-01-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-01-16 · Exercise / conversion · Acquired 67,000 · Balance 67,000 Row 2 · 2018-01-16 · Sale · Disposed 64,405 · Balance 2,595 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $89.54 to $90.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 3 · 2018-01-16 · Sale · Disposed 2,595 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $90.54 to $90.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.73 · Expires 2023-12-20 | Direct | 39,931 |
Reported balance
After 2018-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-16 · Exercise / conversion · Disposed 39,374 · Balance 39,931 F4: The options vested on September 23, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.73 · Expires 2023-12-20 | Direct | 117,669 |
Reported balance
After 2018-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-01-16 · Exercise / conversion · Disposed 27,626 · Balance 117,669 F5: The options vested on March 2, 2016 upon satisfaction of certain performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $89.54 to $90.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $90.54 to $90.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The options vested on September 23, 2017.
F5: The options vested on March 2, 2016 upon satisfaction of certain performance criteria.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,899 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 23 · Balance 2,899 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 57 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 57 · Balance 57 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 18:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 16,077 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001104659-26-071724 · tm2617191-4_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,077 Underlying: Common Stock · 16,077 shares Expires 2033-06-05 F2 · derivative.exercise_date: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 18:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 10,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071724 · tm2617191-4_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,099 F1 · security: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:12 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 57 | $0.00 Strike: $319.44 | $0.00 |
DisclosureSEC source: 0001000697-26-000071 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57 Underlying: Common Stock · 57 shares Expires 2036-02-25 F2 · shares: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:12 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 23 | $0.00 | $0.00 |
DisclosureSEC source: 0001000697-26-000071 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,899 F1 · shares: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:40 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 828 | $0.00 Strike: $381.96 | $0.00 |
DisclosureSEC source: 0001000697-26-000021 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828 Underlying: Common Stock · 828 shares Expires 2036-01-02 F2 · shares: All of the shares of common stock underlying this stock option will vest and become exercisable on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:40 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0001000697-26-000021 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,876 F1 · shares: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on January 2, 2027. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 41,098 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058266 · tm2517578-1_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,098 Underlying: Common Stock · 41,098 shares Expires 2032-06-06 F2 · derivative.exercise_date: 1/12th of the options vest on the 6th of the month for twelve months beginning July 6, 2025. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 23,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058266 · tm2517578-1_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,749 F1 · security: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:03 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 818 | $0.00 Strike: $368.26 | $0.00 |
DisclosureSEC source: 0001127602-25-000637 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818 Underlying: Common Stock · 818 shares Expires 2035-01-02 F2 · shares: Options vest in full on January 2, 2026. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:03 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 319 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000637 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,569 F1 · shares: Represents shares of restricted stock which will vest in full on January 2, 2026. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063966 · tm2415098-4_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063966 · tm2415098-4_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,535 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036282 · tm249281-2_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F2 · derivative.exercise_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. F2 · derivative.expiration_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036282 · tm249281-2_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 15:08 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 500 | $355.54 | $177,770.00 |
DisclosureSEC source: 0001127602-24-010061 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:10 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 847 | $0.00 Strike: $328.62 | $0.00 |
DisclosureSEC source: 0001127602-24-000227 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847 Underlying: Common Stock · 847 shares Expires 2034-01-03 F2 · shares: Options fully vest on January 3, 2025 Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:10 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-000227 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 F1 · shares: Grants of shares of common stock subject to restrictions that lapse January 3, 2025 Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:28 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 15,125 | $0.00 Strike: $20.05 | $0.00 |
DisclosureSEC source: 0001104659-23-061523 · tm2316016-6_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 Underlying: Common Stock · 15,125 shares Expires 2030-05-12 F2 · derivative.exercise_date: 1/12th of the options vest on the 12th of the month for twelve months beginning June 12, 2023. Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:28 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 8,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061523 · tm2316016-6_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,579 F1 · security: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:16 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033874 · tm239899-4_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111 Underlying: Common Stock · 1,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2023. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F2 · derivative.exercise_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2023. F2 · derivative.expiration_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2023. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:16 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033874 · tm239899-4_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 827 | $0.00 Strike: $345.59 | $0.00 |
DisclosureSEC source: 0001127602-23-000744 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 827 shares Expires 2033-01-03 F2 · shares: Options fully vest on January 3, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 318 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000744 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,416 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 3, 2024 Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055441 · tm2214402-6_4seq1.xml · derivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. F2 · derivative.expiration_date: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055441 · tm2214402-6_4seq1.xml · nonDerivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 13,981 | $0.00 Strike: $22.56 | $0.00 |
DisclosureSEC source: 0001104659-22-055441 · tm2214402-6_4seq1.xml · derivative · entry 4 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,891 Underlying: Common Stock · 13,981 shares Expires 2029-04-29 F3 · derivative.exercise_date: 1/12th of the options vest on the 30th of the month for twelve months beginning May 30, 2022. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 7,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055441 · tm2214402-6_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,655 F1 · security: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 22:59 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-034626 · tm229493-1_4seq1.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,222 Underlying: Common Stock · 1,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2022. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F2 · derivative.exercise_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2022. F2 · derivative.expiration_date: The originally granted restricted stock rights vest in three equal annual installments beginning March 15, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 15, 2022. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 22:59 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-034626 · tm229493-1_4seq1.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:12 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 983 | $0.00 Strike: $364.59 | $0.00 |
DisclosureSEC source: 0001127602-22-000752 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 983 Underlying: Common Stock · 983 shares Expires 2032-01-03 F2 · shares: Options fully vest on January 3, 2023 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:12 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 301 | $364.59 | $109,741.59 |
DisclosureSEC source: 0001127602-22-000752 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 3, 2023 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:39 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,260 | $0.00 Strike: $183.41 | $0.00 |
DisclosureSEC source: 0001127602-21-023820 · form4.xml · derivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 1,260 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:39 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 1,260 | $408.99 | $515,327.40 |
DisclosureSEC source: 0001127602-21-023820 · form4.xml · nonDerivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,797 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:39 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 1,260 | $183.41 | $231,096.60 |
DisclosureSEC source: 0001127602-21-023820 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 14:37 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,249 | $0.00 Strike: $188.26 | $0.00 |
DisclosureSEC source: 0001127602-21-016705 · form4.xml · derivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,249 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 14:37 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 1,249 | $314.99 | $393,422.51 |
DisclosureSEC source: 0001127602-21-016705 · form4.xml · nonDerivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,797 Read SEC document |
| May 13, 2021 Filed May 14, 2021 14:37 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 1,249 | $188.26 | $235,136.74 |
DisclosureSEC source: 0001127602-21-016705 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:41 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-063248 · tm2115610d1_4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 2,708 shares Expires 2022-04-30 F2 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:41 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 5,416 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001104659-21-063248 · tm2115610d1_4.xml · derivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 5,416 shares Expires 2028-04-30 F1 · derivative.exercise_date: 1/12th of options vest on the 30th of the month for twelve months beginning May 30, 2021. Read SEC document |
| April 29, 2021 Filed May 24, 2021 22:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-071380 · tm2117431d1_4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Rights convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 15, 2021, the reporting person was grated 341 Restricted Stock Rights that vested on April 29, 2021. F2 · derivative.expiration_date: On March 15, 2021, the reporting person was grated 341 Restricted Stock Rights that vested on April 29, 2021. Read SEC document |
| April 29, 2021 Filed May 24, 2021 22:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-071380 · tm2117431d1_4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Rights convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:56 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-037756 · tm2110061d2_form4.xml · derivative · entry 4 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F4 · derivative.exercise_date: The restricted stock rights vest in three equal annual installments beginning March 15, 2022. F4 · derivative.expiration_date: The restricted stock rights vest in three equal annual installments beginning March 15, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:56 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-037756 · tm2110061d2_form4.xml · derivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341 Underlying: Common Stock · 341 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F3 · derivative.exercise_date: The restricted stock rights vest on April 29, 2021. F3 · derivative.expiration_date: The restricted stock rights vest on April 29, 2021. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:56 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 683 | $0.00 Strike: $57.87 | $0.00 |
DisclosureSEC source: 0001104659-21-037756 · tm2110061d2_form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683 Underlying: Common Stock · 683 shares Expires 2028-03-15 F2 · derivative.exercise_date: 228 options vest on March 30, 2021. The remaining 455 options vest on April 29, 2021. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:56 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 6,667 | $0.00 Strike: $57.87 | $0.00 |
DisclosureSEC source: 0001104659-21-037756 · tm2110061d2_form4.xml · derivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2028-03-15 F1 · derivative.exercise_date: 1/36th of options vest on the 15th of the month for thirty-six months beginning April 15, 2021. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:46 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,352 | $0.00 Strike: $250.15 | $0.00 |
DisclosureSEC source: 0001127602-21-000948 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352 Underlying: Common Stock · 1,352 shares Expires 2031-01-04 F2 · shares: Options fully vest on January 4, 2022. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:46 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 439 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-000948 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,797 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 4, 2022 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:36 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,601 | $0.00 Strike: $235.06 | $0.00 |
DisclosureSEC source: 0001127602-20-000486 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601 Underlying: Common Stock · 1,601 shares Expires 2030-01-02 F2 · derivative.exercise_date: Options fully vest on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:36 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 467 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-000486 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 2, 2021. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:34 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,760 | $0.00 Strike: $183.41 | $0.00 |
DisclosureSEC source: 0001127602-19-001129 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,760 Underlying: Common Stock · 1,760 shares Expires 2029-01-02 F2 · derivative.exercise_date: Options fully vest on January 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.